|
1
|
Patel V, Saxena S, Lund C, Thornicroft G,
Baingana F, Bolton P, Chisholm D, Collins PY, Cooper JL, Eaton J,
et al: The lancet commission on global mental health and
sustainable development. Lancet. 392:1553–1598. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
GBD 2019 Demographics Collaborators.
Global age-sex-specific fertility, mortality, healthy life
expectancy (HALE), and population estimates in 204 countries and
territories, 1950-2019: A comprehensive demographic analysis for
the Global Burden of Disease Study 2019. Lancet. 396:1160–1203.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
GBD 2019 Diseases and Injuries
Collaborators. Global burden of 369 diseases and injuries in 204
countries and territories, 1990-2019: A systematic analysis for the
Global Burden of Disease Study 2019. Lancet. 396:1204–1222.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
GBD 2019 Mental Disorders Collaborators.
Global, regional, and national burden of 12 mental disorders in 204
countries and territories, 1990-2019: A systematic analysis for the
Global Burden of Disease Study 2019. Lancet Psychiatry. 9:137–150.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Khavari B and Cairns MJ: Epigenomic
dysregulation in schizophrenia: In search of disease etiology and
biomarkers. Cells. 9(1837)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
McCutcheon RA, Reis Marques T and Howes
OD: Schizophrenia-an overview. JAMA Psychiatry. 77:201–210.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Saha S, Chant D, Welham J and McGrath J: A
systematic review of the prevalence of schizophrenia. PLoS Med.
2(e141)2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jauhar S, Johnstone M and McKenna PJ:
Schizophrenia. Lancet. 399:473–486. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bueno-Antequera J and Munguía-Izquierdo D:
Exercise and Schizophrenia. Adv Exp Med Biol. 1228:317–332.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Correll CU and Schooler NR: Negative
symptoms in schizophrenia: A review and clinical guide for
recognition, assessment, and treatment. Neuropsychiatr Dis Treat.
16:519–534. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Faden J and Citrome L: Schizophrenia: One
name, many different manifestations. Med Clin North Am. 107:61–72.
2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Javitt DC: Cognitive impairment associated
with schizophrenia: From pathophysiology to treatment. Annu Rev
Pharmacol Toxicol. 63:119–141. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ma H, Cheng N and Zhang C: Schizophrenia
and alarmins. Medicina (Kaunas). 58(694)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zamanpoor M: Schizophrenia in a genomic
era: A review from the pathogenesis, genetic and environmental
etiology to diagnosis and treatment insights. Psychiatr Genet.
30:1–9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chauhan P, Kaur G, Prasad R and Singh H:
Pharmacotherapy of schizophrenia: Immunological aspects and
potential role of immunotherapy. Expert Rev Neurother.
21:1441–1453. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Helaly AMN and Ghorab DSED: Schizophrenia
as metabolic disease. What are the causes? Metab Brain Dis.
38:795–804. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Stilo SA and Murray RM: Non-genetic
factors in schizophrenia. Curr Psychiatry Rep.
21(100)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Collins FS, Morgan M and Patrinos A: The
human genome project: Lessons from large-scale biology. Science.
300:286–290. 2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Peedicayil J: Genome-environment
interactions and psychiatric disorders. Biomedicines.
11(1209)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tsuang M: Schizophrenia: Genes and
environment. Biol Psychiatry. 47:210–220. 2000.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kendler KS and Diehl SR: The genetics of
schizophrenia: A current, genetic-epidemiologic perspective.
Schizophr Bull. 19:261–285. 1993.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wahbeh MH and Avramopoulos D:
Gene-environment interactions in schizophrenia: A literature
review. Genes (Basel). 12(1850)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Takata A, Xu B, Ionita-Laza I, Roos JL,
Gogos JA and Karayiorgou M: Loss-of-function variants in
schizophrenia risk and SETD1A as a candidate susceptibility gene.
Neuron. 82:773–780. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ansari-Lari M, Zendehboodi Z, Masoudian M
and Mohammadi F: Additive effect of glutathione S-transferase T1
active genotype and infection with Toxoplasma gondii for increasing
the risk of schizophrenia. Nord J Psychiatry. 75:275–280.
2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Coyle JT: Passing the torch: The
ascendance of the glutamatergic synapse in the pathophysiology of
schizophrenia. Biochem Pharmacol. 228(116376)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Harrison PJ and Bannerman DM: GRIN2A
(NR2A): A gene contributing to glutamatergic involvement in
schizophrenia. Mol Psychiatry. 28:3568–3572. 2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang CY, Xiao X, Zhang Z, Hu Z and Li M:
An alternative splicing hypothesis for neuropathology of
schizophrenia: evidence from studies on historical candidate genes
and multi-omics data. Mol Psychiatry. 27:95–112. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pardiñas AF, Holmans P, Pocklington AJ,
Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop S, Cameron D,
Hamshere ML, et al: Common schizophrenia alleles are enriched in
mutation-intolerant genes and in regions under strong background
selection. Nat Genet. 50:381–389. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Forsyth JK and Asarnow RF: Genetics of
childhood-onset schizophrenia 2019 update. Child Adolesc Psychiatr
Clin N Am. 29:157–170. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Schizophrenia Working Group of the
Psychiatric Genomics Consortium. Biological insights from 108
schizophrenia-associated genetic loci. Nature. 511:421–427.
2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ambalavanan A, Girard SL, Ahn K, Zhou S,
Dionne-Laporte A, Spiegelman D, Bourassa CV, Gauthier J, Hamdan FF,
Xiong L, et al: De novo variants in sporadic cases of childhood
onset schizophrenia. Eur J Hum Genet. 24:944–948. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chaumette B, Ferrafiat V, Ambalavanan A,
Goldenberg A, Dionne-Laporte A, Spiegelman D, Dion PA, Gerardin P,
Laurent C, Cohen D, et al: Missense variants in ATP1A3 and FXYD
gene family are associated with childhood-onset schizophrenia. Mol
Psychiatry. 25:821–830. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Smedemark-Margulies N, Brownstein CA,
Vargas S, Tembulkar SK, Towne MC, Shi J, Gonzalez-Cuevas E, Liu KX,
Bilguvar K, Kleiman RJ, et al: A novel de novo mutation in ATP1A3
and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud.
2(a001008)2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jolly LA, Homan CC, Jacob R, Barry S and
Gecz J: The UPF3B gene, implicated in intellectual disability,
autism, ADHD and childhood onset schizophrenia regulates neural
progenitor cell behaviour and neuronal outgrowth. Hum Mol Genet.
22:4673–4687. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Richetto J and Meyer U: Epigenetic
modifications in schizophrenia and related disorders: Molecular
scars of environmental exposures and source of phenotypic
variability. Biol Psychiatry. 89:215–226. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Guidotti A, Grayson DR and Caruncho HJ:
Epigenetic RELN dysfunction in schizophrenia and related
neuropsychiatric disorders. Front Cell Neurosci.
10(89)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jaffe AE, Gao Y, Deep-Soboslay A, Tao R,
Hyde TM, Weinberger DR and Kleinman JE: Mapping DNA methylation
across development, genotype and schizophrenia in the human frontal
cortex. Nat Neurosci. 19:40–47. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sharma RP, Rosen C, Kartan S, Guidotti A,
Costa E, Grayson DR and Chase K: Valproic acid and chromatin
remodeling in schizophrenia and bipolar disorder: Preliminary
results from a clinical population. Schizophr Res. 88:227–231.
2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Akbarian S, Ruehl MG, Bliven E, Luiz LA,
Peranelli AC, Baker SP, Roberts RC, Bunney WE Jr, Conley RC, Jones
EG, et al: Chromatin alterations associated with down-regulated
metabolic gene expression in the prefrontal cortex of subjects with
schizophrenia. Arch Gen Psychiatry. 62:829–840. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bahari-Javan S, Varbanov H, Halder R,
Benito E, Kaurani L, Burkhardt S, Anderson-Schmidt H, Anghelescu I,
Budde M, Stilling RM, et al: HDAC1 links early life stress to
schizophrenia-like phenotypes. Proc Natl Acad Sci USA.
114:E4686–E4694. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Schroeder FA, Gilbert TM, Feng N, Taillon
BD, Volkow ND, Innis RB, Hooker JM and Lipska BK: Expression of
HDAC2 but Not HDAC1 transcript is reduced in dorsolateral
prefrontal cortex of patients with schizophrenia. ACS Chem
Neurosci. 8:662–668. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Dickerson F, Schroeder JR, Nimgaonkar V,
Gold J and Yolken R: The association between exposure to herpes
simplex virus type 1 (HSV-1) and cognitive functioning in
schizophrenia: A meta-analysis. Psychiatry Res.
291(113157)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tripathy S, Singh N, Singh A and Kar SK:
COVID-19 and psychotic symptoms: The view from psychiatric
immunology. Curr Behav Neurosci Rep. 8:172–178. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Banerjee D and Viswanath B:
Neuropsychiatric manifestations of COVID-19 and possible pathogenic
mechanisms: Insights from other coronaviruses. Asian J Psychiatr.
54(102350)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Klein HC, Guest PC, Dobrowolny H and
Steiner J: Inflammation and viral infection as disease modifiers in
schizophrenia. Front Psychiatry. 14(1231750)2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pandey JP, Namboodiri AM and Elston RC:
Immunoglobulin G genotypes and the risk of schizophrenia. Hum
Genet. 135:1175–1179. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Inyang B, Gondal FJ, Abah GA, Minnal
Dhandapani M, Manne M, Khanna M, Challa S, Kabeil AS and Mohammed
L: The role of childhood trauma in psychosis and schizophrenia: A
systematic review. Cureus. 14(e21466)2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Thomson P and Jaque SV: Childhood
adversity and the creative experience in adult professional
performing artists. Front Psychol. 9(111)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Buscemi V, Chang WJ, Liston MB, McAuley JH
and Schabrun S: The role of psychosocial stress in the development
of chronic musculoskeletal pain disorders: Protocol for a
systematic review and meta-analysis. Syst Rev.
6(224)2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Li KJ, Chen A and DeLisi LE: Opioid use
and schizophrenia. Curr Opin Psychiatry. 33:219–224.
2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Guloksuz S, Rutten BPF, Pries LK, Ten Have
M, de Graaf R, van Dorsselaer S, Klingenberg B, van Os J and
Ioannidis JPA: European Network of National Schizophrenia Networks
Studying Gene-Environment Interactions Work Package 6 (EU-GEI WP6)
Group. The complexities of evaluating the exposome in psychiatry: A
data-driven illustration of challenges and some propositions for
amendments. Schizophr Bull. 44:1175–1179. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Rodriguez-Gonzalez A and Orio L:
Microbiota and alcohol use disorder: Are psychobiotics a novel
therapeutic strategy? Curr Pharm Des. 26:2426–2437. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Clausing ES and Non AL: Epigenetics as a
mechanism of developmental embodiment of stress, resilience, and
cardiometabolic risk across generations of latinx immigrant
families. Front Psychiatry. 12(696827)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Jaaro-Peled H and Sawa A:
Neurodevelopmental factors in schizophrenia. Psychiatr Clin North
Am. 43:263–274. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Karlsson H and Dalman C: Epidemiological
studies of prenatal and childhood infection and schizophrenia. Curr
Top Behav Neurosci. 44:35–47. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ju S, Shin Y, Han S, Kwon J, Choi TG, Kang
I and Kim SS: The gut-brain axis in schizophrenia: The implications
of the gut microbiome and SCFA production. Nutrients.
15(4391)2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Tandon R, Nasrallah H, Akbarian S,
Carpenter WT Jr, DeLisi LE, Gaebel W, Green MF, Gur RE, Heckers S,
Kane JM, et al: The schizophrenia syndrome, circa 2024: What we
know and how that informs its nature. Schizophr Res. 264:1–28.
2024.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Al-Haddad BJS, Oler E, Armistead B,
Elsayed NA, Weinberger DR, Bernier R, Burd I, Kapur R, Jacobsson B,
Wang C, et al: The fetal origins of mental illness. Am J Obstet
Gynecol. 221:549–562. 2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Desmettre T: Toxoplasmosis and behavioural
changes. J Fr Ophtalmol. 43:e89–e93. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Maldonado YA and Read JS: COMMITTEE ON
INFECTIOUS DISEASES. Diagnosis, treatment, and prevention of
congenital toxoplasmosis in the United States. Pediatrics.
139(e20163860)2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Chen X, Chen B, Hou X, Zheng C, Yang X, Ke
J, Hu X and Tan F: Association between Toxoplasma gondii infection
and psychiatric disorders in Zhejiang, Southeastern China. Acta
Trop. 192:82–86. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Liu T, Gao P, Bu D and Liu D: Association
between Toxoplasma gondii infection and psychiatric disorders: A
cross-sectional study in China. Sci Rep. 12(15092)2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Veleva I, Stoychev K, Stoimenova-Popova M,
Stoyanov L, Mineva-Dimitrova E and Angelov I: Toxoplasma gondii
seropositivity and cognitive function in adults with schizophrenia.
Schizophr Res Cogn. 30(100269)2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Acquarone M, Poleto A, Perozzo AF,
Gonçalves PFR, Panizzutti R, Menezes JRL, Neves GA and Barbosa HS:
Social preference is maintained in mice with impaired startle
reflex and glutamate/D-serine imbalance induced by chronic cerebral
toxoplasmosis. Sci Rep. 11(14029)2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lucchese G: From toxoplasmosis to
schizophrenia via NMDA dysfunction: Peptide overlap between
toxoplasma gondii and N-Methyl-d-Aspartate receptors as a potential
mechanistic link. Front Psychiatry. 8(37)2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Bhavsar V, Boydell J, McGuire P, Harris V,
Hotopf M, Hatch SL, MacCabe JH and Morgan C: Childhood abuse and
psychotic experiences-evidence for mediation by adulthood adverse
life events. Epidemiol Psychiatr Sci. 28:300–309. 2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Sheffield JM, Karcher NR and Barch DM:
Cognitive deficits in psychotic disorders: A lifespan perspective.
Neuropsychol Rev. 28:509–533. 2018.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Kaufman J and Torbey S: Child maltreatment
and psychosis. Neurobiol Dis. 131(104378)2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Powers A, Fani N, Cross D, Ressler KJ and
Bradley B: Childhood trauma, PTSD, and psychosis: Findings from a
highly traumatized, minority sample. Child Abuse Negl. 58:111–118.
2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Vila-Badia R, Butjosa A, Del Cacho N,
Serra-Arumí C, Esteban-Sanjusto M, Ochoa S and Usall J: Types,
prevalence and gender differences of childhood trauma in
first-episode psychosis. What is the evidence that childhood trauma
is related to symptoms and functional outcomes in first episode
psychosis? A systematic review. Schizophr Res. 228:159–179.
2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Abdel-Baki A, Ouellet-Plamondon C, Salvat
É, Grar K and Potvin S: Symptomatic and functional outcomes of
substance use disorder persistence 2 years after admission to a
first-episode psychosis program. Psychiatry Res. 247:113–119.
2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Di Forti M, Quattrone D, Freeman TP,
Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE,
Ferraro L, La Cascia C, et al: The contribution of cannabis use to
variation in the incidence of psychotic disorder across Europe
(EU-GEI): A multicentre case-control study. Lancet Psychiatry.
6:427–436. 2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Morgan C, Charalambides M, Hutchinson G
and Murray RM: Migration, ethnicity, and psychosis: Toward a
sociodevelopmental model. Schizophr Bull. 36:655–664.
2010.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Porter M and Haslam N: Predisplacement and
postdisplacement factors associated with mental health of refugees
and internally displaced persons: A meta-analysis. JAMA.
294:602–612. 2005.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Veling W, Selten JP, Susser E, Laan W,
Mackenbach JP and Hoek HW: Discrimination and the incidence of
psychotic disorders among ethnic minorities in The Netherlands. Int
J Epidemiol. 36:761–768. 2007.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Benros ME and Mortensen PB: Role of
infection, autoimmunity, atopic disorders, and the immune system in
schizophrenia: Evidence from epidemiological and genetic studies.
Curr Top Behav Neurosci. 44:141–159. 2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wang AW, Avramopoulos D, Lori A, Mulle J,
Conneely K, Powers A, Duncan E, Almli L, Massa N, McGrath J, et al:
Genome-wide association study in two populations to determine
genetic variants associated with Toxoplasma gondii infection and
relationship to schizophrenia risk. Prog Neuropsychopharmacol Biol
Psychiatry. 92:133–147. 2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Lori A, Avramopoulos D, Wang AW, Mulle J,
Massa N, Duncan EJ, Powers A, Conneely K, Gillespie CF, Jovanovic
T, et al: Polygenic risk scores differentiate schizophrenia
patients with toxoplasma gondii compared to toxoplasma seronegative
patients. Compr Psychiatry. 107(152236)2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Xiao J, Prandovszky E, Kannan G, Pletnikov
MV, Dickerson F, Severance EG and Yolken RH: Toxoplasma gondii:
Biological parameters of the connection to schizophrenia. Schizophr
Bull. 44:983–992. 2018.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Hong J and Bang M: Anti-inflammatory
strategies for schizophrenia: A review of evidence for therapeutic
applications and drug repurposing. Clin Psychopharmacol Neurosci.
18:10–24. 2020.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Avramopoulos D, Pearce BD, McGrath J,
Wolyniec P, Wang R, Eckart N, Hatzimanolis A, Goes FS, Nestadt G,
Mulle J, et al: Infection and inflammation in schizophrenia and
bipolar disorder: A genome wide study for interactions with genetic
variation. PLoS One. 10(e0116696)2015.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Estes ML and McAllister AK: Maternal
immune activation: Implications for neuropsychiatric disorders.
Science. 353:772–777. 2016.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Reisinger S, Khan D, Kong E, Berger A,
Pollak A and Pollak DD: The poly(I:C)-induced maternal immune
activation model in preclinical neuropsychiatric drug discovery.
Pharmacol Ther. 149:213–226. 2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Caspi A, Moffitt TE, Cannon M, McClay J,
Murray R, Harrington H, Taylor A, Arseneault L, Williams B,
Braithwaite A, et al: Moderation of the effect of adolescent-onset
cannabis use on adult psychosis by a functional polymorphism in the
catechol-O-methyltransferase gene: longitudinal evidence of a gene
X environment interaction. Biol Psychiatry. 57:1117–1127.
2005.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Zammit S, Spurlock G, Williams H, Norton
N, Williams N, O'Donovan MC and Owen MJ: Genotype effects of
CHRNA7, CNR1 and COMT in schizophrenia: Interactions with tobacco
and cannabis use. Br J Psychiatry. 191:402–407. 2007.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Akhtar MJ, Yar MS, Grover G and Nath R:
Neurological and psychiatric management using COMT inhibitors: A
review. Bioorg Chem. 94(103418)2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Henquet C, Rosa A, Krabbendam L, Papiol S,
Fananás L, Drukker M, Ramaekers JG and van Os J: An experimental
study of catechol-o-methyltransferase Val158Met moderation of
delta-9-tetrahydrocannabinol-induced effects on psychosis and
cognition. Neuropsychopharmacology. 31:2748–2757. 2006.PubMed/NCBI View Article : Google Scholar
|
|
88
|
van Winkel R, Stefanis NC and Myin-Germeys
I: Psychosocial stress and psychosis. A review of the
neurobiological mechanisms and the evidence for gene-stress
interaction. Schizophr Bull. 34:1095–1105. 2008.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Hindocha C, Quattrone D, Freeman TP,
Murray RM, Mondelli V, Breen G, Curtis C, Morgan CJA, Valerie
Curran H and Di Forti M: Do AKT1, COMT and FAAH influence reports
of acute cannabis intoxication experiences in patients with first
episode psychosis, controls and young adult cannabis users? Transl
Psychiatry. 10(143)2020.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Hiemstra M, Nelemans SA, Branje S, van
Eijk KR, Hottenga JJ, Vinkers CH, van Lier P, Meeus W and Boks MP:
Genetic vulnerability to schizophrenia is associated with cannabis
use patterns during adolescence. Drug Alcohol Depend. 190:143–150.
2018.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Dzirasa K and Covington HE 3rd: Increasing
the validity of experimental models for depression. Ann N Y Acad
Sci. 1265:36–45. 2012.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Hvoslef-Eide M, Mar AC, Nilsson SR, Alsiö
J, Heath CJ, Saksida LM, Robbins TW and Bussey TJ: The NEWMEDS
rodent touchscreen test battery for cognition relevant to
schizophrenia. Psychopharmacology (Berl). 232:3853–3872.
2015.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Modinos G, Allen P, Grace AA and McGuire
P: Translating the MAM model of psychosis to humans. Trends
Neurosci. 38:129–138. 2015.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Talamini LM, Ellenbroek B, Koch T and Korf
J: Impaired sensory gating and attention in rats with developmental
abnormalities of the mesocortex. Implications for schizophrenia.
Ann N Y Acad Sci. 911:486–494. 2000.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Paylor JW, Lins BR, Greba Q, Moen N, de
Moraes RS, Howland JG and Winship IR: Developmental disruption of
perineuronal nets in the medial prefrontal cortex after maternal
immune activation. Sci Rep. 6(37580)2016.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Steullet P, Cabungcal JH, Coyle J,
Didriksen M, Gill K, Grace AA, Hensch TK, LaMantia AS, Lindemann L,
Maynard TM, et al: Oxidative stress-driven parvalbumin interneuron
impairment as a common mechanism in models of schizophrenia. Mol
Psychiatry. 22:936–943. 2017.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Careaga M, Murai T and Bauman MD: Maternal
immune activation and autism spectrum disorder: From rodents to
nonhuman and human primates. Biol Psychiatry. 81:391–401.
2017.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Sams-Dodd F: A test of the predictive
validity of animal models of schizophrenia based on phencyclidine
and D-amphetamine. Neuropsychopharmacology. 18:293–304.
1998.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Kittirattanapaiboon P, Mahatnirunkul S,
Booncharoen H, Thummawomg P, Dumrongchai U and Chutha W: Long-term
outcomes in methamphetamine psychosis patients after first
hospitalisation. Drug Alcohol Rev. 29:456–461. 2010.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Lecomte T, Dumais A, Dugré JR and Potvin
S: The prevalence of substance-induced psychotic disorder in
methamphetamine misusers: A meta-analysis. Psychiatry Res.
268:189–192. 2018.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Medhus S, Rognli EB, Gossop M, Holm B,
Mørland J and Bramness JG: Amphetamine-induced psychosis:
Transition to schizophrenia and mortality in a small prospective
sample. Am J Addict. 24:586–589. 2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Wearne TA, Mirzaei M, Franklin JL,
Goodchild AK, Haynes PA and Cornish JL: Methamphetamine-induced
sensitization is associated with alterations to the proteome of the
prefrontal cortex: Implications for the maintenance of psychotic
disorders. J Proteome Res. 14:397–410. 2015.PubMed/NCBI View Article : Google Scholar
|
|
103
|
El-Sayed El-Sisi A, Sokkar SS, El-Sayed
El-Sayad M, Sayed Ramadan E and Osman EY: Celecoxib and omega-3
fatty acids alone and in combination with risperidone affect the
behavior and brain biochemistry in amphetamine-induced model of
schizophrenia. Biomed Pharmacother. 82:425–431. 2016.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Kalinichev M, Robbins MJ, Hartfield EM,
Maycox PR, Moore SH, Savage KM, Austin NE and Jones DN: Comparison
between intraperitoneal and subcutaneous phencyclidine
administration in Sprague-Dawley rats: A locomotor activity and
gene induction study. Prog Neuropsychopharmacol Biol Psychiatry.
32:414–422. 2008.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Dennison CA, Legge SE, Pardiñas AF and
Walters JTR: Genome-wide association studies in schizophrenia:
Recent advances, challenges and future perspective. Schizophr Res.
217:4–12. 2020.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Keller MC: Evolutionary perspectives on
genetic and environmental risk factors for psychiatric disorders.
Annu Rev Clin Psychol. 14:471–493. 2018.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Power RA, Kyaga S, Uher R, MacCabe JH,
Långström N, Landen M, McGuffin P, Lewis CM, Lichtenstein P and
Svensson AC: Fecundity of patients with schizophrenia, autism,
bipolar disorder, depression, anorexia nervosa, or substance abuse
vs their unaffected siblings. JAMA Psychiatry. 70:22–30.
2013.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Bray NJ, Kapur S and Price J:
Investigating schizophrenia in a ‘dish’: Possibilities, potential
and limitations. World Psychiatry. 11:153–155. 2012.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Kovalevich J and Langford D:
Considerations for the use of SH-SY5Y neuroblastoma cells in
neurobiology. Methods Mol Biol. 1078:9–21. 2013.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Bell M, Bachmann S, Klimek J,
Langerscheidt F and Zempel H: Axonal TAU sorting requires the
C-terminus of TAU but is independent of ANKG and TRIM46 Enrichment
at the AIS. Neuroscience. 461:155–171. 2021.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Paik S, Somvanshi RK and Kumar U:
Somatostatin-mediated changes in microtubule-associated proteins
and retinoic acid-induced neurite outgrowth in SH-SY5Y cells. J Mol
Neurosci. 68:120–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Farber NB, Wozniak DF, Price MT, Labruyere
J, Huss J, St Peter H and Olney JW: Age-specific neurotoxicity in
the rat associated with NMDA receptor blockade: Potential relevance
to schizophrenia? Biol Psychiatry. 38:788–796. 1995.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Berdenis van Berlekom A, Muflihah CH,
Snijders GJLJ, MacGillavry HD, Middeldorp J, Hol EM, Kahn RS and de
Witte LD: Synapse pathology in schizophrenia: A meta-analysis of
postsynaptic elements in postmortem brain studies. Schizophr Bull.
46:374–386. 2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Piñero-Martos E, Ortega-Vila B, Pol-Fuster
J, Cisneros-Barroso E, Ruiz-Guerra L, Medina-Dols A, Heine-Suñer D,
Lladó J, Olmos G and Vives-Bauzà C: Disrupted in schizophrenia 1
(DISC1) is a constituent of the mammalian mitochondrial contact
site and cristae organizing system (MICOS) complex, and is
essential for oxidative phosphorylation. Hum Mol Genet.
25:4157–4169. 2016.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Peykov S, Berkel S, Schoen M, Weiss K,
Degenhardt F, Strohmaier J, Weiss B, Proepper C, Schratt G, Nöthen
MM, et al: Identification and functional characterization of rare
SHANK2 variants in schizophrenia. Mol Psychiatry. 20:1489–1498.
2015.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Unsicker C, Cristian FB, von Hahn M,
Eckstein V, Rappold GA and Berkel S: SHANK2 mutations impair
apoptosis, proliferation and neurite outgrowth during early
neuronal differentiation in SH-SY5Y cells. Sci Rep.
11(2128)2021.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Wu S, Wang P, Tao R, Yang P, Yu X, Li Y,
Shao Q, Nie F, Ha J, Zhang R, et al: Schizophrenia-associated
microRNA-148b-3p regulates COMT and PRSS16 expression by targeting
the ZNF804A gene in human neuroblastoma cells. Mol Med Rep.
22:1429–1439. 2020.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Toyoshima M, Akamatsu W, Okada Y, Ohnishi
T, Balan S, Hisano Y, Iwayama Y, Toyota T, Matsumoto T, Itasaka N,
et al: Analysis of induced pluripotent stem cells carrying 22q11.2
deletion. Transl Psychiatry. 6(e934)2016.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Lee IS, Carvalho CM, Douvaras P, Ho SM,
Hartley BJ, Zuccherato LW, Ladran IG, Siegel AJ, McCarthy S,
Malhotra D, et al: Characterization of molecular and cellular
phenotypes associated with a heterozygous CNTNAP2 deletion using
patient-derived hiPSC neural cells. NPJ Schizophr. 1:15019-.
2015.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X,
Su Y, Kim NS, Yoon KJ, Shin J, Zhang C, et al: Synaptic
dysregulation in a human iPS cell model of mental disorders.
Nature. 515:414–418. 2014.PubMed/NCBI View Article : Google Scholar
|
|
121
|
McCutcheon RA, Krystal JH and Howes OD:
Dopamine and glutamate in schizophrenia: Biology, symptoms and
treatment. World Psychiatry. 19:15–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Cohen SM, Tsien RW, Goff DC and Halassa
MM: The impact of NMDA receptor hypofunction on GABAergic neurons
in the pathophysiology of schizophrenia. Schizophr Res. 167:98–107.
2015.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Raabe FJ, Slapakova L, Rossner MJ,
Cantuti-Castelvetri L, Simons M, Falkai PG and Schmitt A:
Oligodendrocytes as a new therapeutic target in schizophrenia: From
histopathological findings to neuron-oligodendrocyte interaction.
Cells. 8(1496)2019.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Tran NN, Ladran IG and Brennand KJ:
Modeling schizophrenia using induced pluripotent stem cell-derived
and fibroblast-induced neurons. Schizophr Bull. 39:4–10.
2013.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Liu Y, Pham X, Zhang L, Chen PL, Burzynski
G, McGaughey DM, He S, McGrath JA, Wolyniec P, Fallin MD, et al:
Functional variants in DPYSL2 sequence increase risk of
schizophrenia and suggest a link to mTOR signaling. G3 (Bethesda).
5:61–72. 2014.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Stratton H, Boinon L, Moutal A and Khanna
R: Coordinating synaptic signaling with CRMP2. Int J Biochem Cell
Biol. 124(105759)2020.PubMed/NCBI View Article : Google Scholar
|
